<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dosing of antibiotics for &lt;em&gt;Acinetobacter&lt;/em&gt; infections in adults with normal renal function</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dosing of antibiotics for <em>Acinetobacter</em> infections in adults with normal renal function</h1>
<div class="graphic"><div class="figure"><div class="ttl">Dosing of antibiotics for <em>Acinetobacter</em> infections in adults with normal renal function</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup> <colgroup width="80%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Dose</td> </tr> <tr> <td class="subtitle2_left" colspan="2">First-line agents</td> </tr> <tr> <td class="indent1">Ceftazidime</td> <td>2 g intravenously every 8 hours (infuse each dose over 3 to 4 <span class="nowrap_whitespace">hours)<sup>*</sup></span></td> </tr> <tr> <td class="indent1">Cefepime</td> <td>2 g intravenously every 8 hours (infuse each dose over 3 to 4 <span class="nowrap_whitespace">hours)<sup>*</sup></span></td> </tr> <tr> <td class="indent1">Piperacillin-tazobactam</td> <td>4.5 g intravenously every 8 hours (infuse each dose over 4 <span class="nowrap_whitespace">hours)<sup>*</sup></span></td> </tr> <tr> <td class="indent1">Ampicillin-sulbactam<sup>¶</sup></td> <td> <p>Mild carbapenem-susceptible infections: 3 g intravenously every 6 hours</p> <p>Mild carbapenem-resistant infections: 3 g intravenously every 4 hours</p> Moderate to severe infections: 9 g intravenously every 8 hours (infuse each dose over <span class="nowrap_whitespace">4 hours)<sup>*</sup>,</span> <strong>or</strong> 27 g intravenously every 24 hours as a continuous <span class="nowrap_whitespace">infusion<sup>*</sup></span></td> </tr> <tr> <td class="indent1">Sulbactam-durlobactam<sup>Δ</sup></td> <td> <p>Sulbactam 1 g/durlobactam 1g intravenously every 6 hours (infuse each dose over 3 hours)</p> For patients with augmented renal clearance (CrCl ≥130 mL/minute): Sulbactam 1 g/durlobactam 1 g intravenously every 4 hours (infuse each dose over 3 hours)</td> </tr> <tr> <td class="indent1">Meropenem</td> <td> <p>Cystitis: 1 g intravenously every 8 hours (infuse each dose over 30 minutes)</p> Infections other than cystitis: 2 g intravenously every 8 hours (infuse each dose over 3 <span class="nowrap_whitespace">hours)<sup>*</sup></span></td> </tr> <tr> <td class="indent1">Imipenem-cilastatin</td> <td> <p>Cystitis: 500 mg intravenously every 6 hours (infuse each dose over 30 minutes)</p> Infections other than cystitis: 500 mg intravenously every 6 hours, or 1 g intravenously every 6 to 8 hours (infuse each dose over <span class="nowrap_whitespace">3 hours)<sup>*</sup></span></td> </tr> <tr> <td class="indent1">Ciprofloxacin<sup>◊</sup></td> <td>400 mg intravenously every 8 hours, or 750 mg orally every 12 hours</td> </tr> <tr> <td class="indent1">Levofloxacin<sup>◊</sup></td> <td>750 mg intravenously or orally once daily</td> </tr> <tr> <td class="indent1">Trimethoprim-sulfamethoxazole<sup>§</sup></td> <td>Cystitis: 1 double-strength tablet (trimethoprim 160 mg and sulfamethoxazole 800 mg) orally twice daily</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Second-line agents</td> </tr> <tr> <td class="indent1">Colistin (colistimethate)<sup>¥</sup></td> <td> <p><strong>Intravenous dose:</strong> Loading dose of 300 mg CBA (equivalent to approximately 9 million units colistimethate sodium), followed by a daily maintenance dose of 300 to 360 mg CBA (approximately 9 to 11 million units colistimethate sodium) divided into 2 doses infused over 1 hour</p> <strong>Inhaled dose:</strong> 75 to 150 mg CBA (2.25 to 4.5 million units) every 12 hours</td> </tr> <tr> <td class="indent1">Polymyxin B</td> <td>Loading dose of 2 to 2.5 mg/kg (20,000 to 25,000 units/kg), followed by 1.25 to 1.5 mg/kg (12,500 to 15,000 units/kg) every 12 hours; doses should be based on total body weight</td> </tr> <tr> <td class="indent1">Minocycline<sup>‡</sup></td> <td>200 mg intravenously or orally every 12 hours</td> </tr> <tr> <td class="indent1">Doxycycline<sup>‡</sup></td> <td>100 mg intravenously or orally every 12 hours</td> </tr> <tr> <td class="indent1">Tigecycline<sup>‡</sup></td> <td> <p>Mild infections and carbapenem-susceptible infections: 100 mg loading dose, followed by 50 mg intravenously every 12 hours</p> Moderate to severe carbapenem-resistant infections: 200 mg loading dose, followed by 100 mg intravenously every 12 hours</td> </tr> <tr> <td class="indent1">Cefiderocol</td> <td>2 g intravenously every 8 hours (infuse each dose over 3 hours); in patients with creatinine clearance ≥120 mL/minute, administer 2 g intravenously every 6 hours (infuse each dose over 3 hours)</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Agents typically used in combination with another agent</td> </tr> <tr> <td class="indent1">Gentamicin<sup>◊†</sup></td> <td> <p>Cystitis: 5 mg/kg/dose intravenously for 1 dose</p> Infections other than cystitis: 7 mg/kg/dose intravenously for first dose with subsequent doses and dosing intervals based on pharmacokinetic evaluation</td> </tr> <tr> <td class="indent1">Tobramycin<sup>◊†</sup></td> <td> <p>Cystitis: 5 mg/kg/dose intravenously for 1 dose</p> Infections other than cystitis: 7 mg/kg/dose intravenously for first dose with subsequent doses and dosing intervals based on pharmacokinetic evaluation</td> </tr> <tr> <td class="indent1">Amikacin<sup>◊†</sup></td> <td> <p>Cystitis: 15 mg/kg/dose intravenously for 1 dose</p> Infections other than cystitis: 20 mg/kg/dose intravenously for first dose with subsequent doses and dosing intervals based on pharmacokinetic evaluation</td> </tr> </tbody></table></div><div class="graphic_lgnd">This table lists typical doses for use in <em>Acinetobacter</em> infection among patients with normal renal function. Antimicrobial susceptibility should be confirmed for clinical isolates. Higher doses may be warranted for infections of the central nervous system.</div><div class="graphic_footnotes"><p>CBA: colistin base activity; CrCl: creatinine clearance; UTI: urinary tract infection.</p>
<p>* May administer first dose over 30 minutes when rapid attainment of therapeutic drug concentrations is desired.</p>
<p>¶ Sulbactam is the active component. Dose is expressed as sum of ampicillin and sulbactam.</p>
<p>Δ Reserve use of sulbactam-durlobactam for patients with hospital-acquired or ventilator-associated pneumonia or bacteremia due to carbapenem-resistant <em>Acinetobacter baumannii</em> in whom other first-line agents are not an option<sup>[4]</sup>.</p>
<p>◊ For moderate to severe infections, fluoroquinolones are generally used in combination with another agent. Aminoglycosides can be used as monotherapy for mild urinary tract infections; for all other infections, they should be used in combination with another agent.</p>
<p>§ For susceptible UTIs, oral trimethoprim-sulfamethoxazole (TMP-SMX) is an option. However, most <em>Acinetobacter</em> isolates are resistant to TMP-SMX. TMP-SMX is not recommended for infections outside the urinary tract or as part of combination therapy.</p>
<p>¥ Dose is expressed as colistin base activity as in United States licensed product information. 1 mg CBA is approximately 30,000 units (also known as international units) colistimethate sodium. Parenteral dosages should be adjusted based on creatinine clearance and match those recommended in international guidelines<sup>[2]</sup>. For inhaled colistin, optimal dosing is uncertain; doses up to 167 mg CBA (approximately 5 million units colistimethate sodium) inhaled every 8 hours have been used for ventilator-associated pneumonia due to <em>Acinetobacter</em>.</p>
<p>‡ Minocycline, doxycycline, and tigecycline may not reach adequate levels in the serum or urinary tract to successfully treat infections in these compartments.</p>
† For patients &gt;120% of ideal body weight, use adjusted body weight for aminoglycoside dosing.</div><div class="graphic_reference">Reference:
<ol>
<li>Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53:3430.</li>
<li>Tsuji B, Pogue J, Zavascki A, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019; 39:10.</li>
<li>Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis 2022; 75:187.</li>
<li>Xacduro package insert, revised 5/2023. Federal Food and Drug Administration. Available at: <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf</a> (Accessed on October 23, 2023).</li>
</ol></div><div id="graphicVersion">Graphic 72436 Version 18.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
